Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acumen Pharmaceuticals Inc
NASDAQ ABOS
Data sourced from
and
and
Download Data
Acumen Pharmaceuticals Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: 0.91
Acumen Pharmaceuticals Inc Enterprise Value to EBITDA (EV/EBITDA) is 0.91 on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.
-
Acumen Pharmaceuticals Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is 3.53 on March 18, 2024, which is 288.77% above the current Enterprise Value to EBITDA (EV/EBITDA).
-
Acumen Pharmaceuticals Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -0.55 on March 22, 2024, which is -160.91% below the current Enterprise Value to EBITDA (EV/EBITDA).
-
Acumen Pharmaceuticals Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 0.61.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ABOS
| CEO | Mr. Daniel J. O'Connell M.B.A. |
| IPO Date | July 1, 2021 |
| Location | United States |
| Headquarters | 427 Park Street, Charlottesville, VA, United States, 22902 |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email